bullish
Otsuka Holdings (4578 JP): Strong 2022 Result; 2023 Revenue to Hit Record-High Thanks to Key Drugs
569 Views08 Apr 2023 23:37
SUMMARY
- Otsuka Holdings (4578 JP) reported better-than-expected 2022 result. Revenue increased 16% to ¥1,738B and business profit grew 11% to ¥175B, driven by the four global products and the nutraceutical segment.
- Revenue from four global products surged 26% to ¥619B, representing 54% of pharmaceutical revenue. Otsuka expects the momentum to continue and these products to record revenue of ¥637B in 2023.
- For 2023, Otsuka has guided for record-high revenue and net profit of ¥1,800B (+4% YoY) and 158B (+18% YoY), respectively, driven by increased revenue from growth businesses.
Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
- Otsuka Holdings (4578 JP): Impairment Charges Bite 2023 Profit; 2024 Guidance Initiated21 Feb 2024
- Otsuka Holdings (4578 JP): Global Products Continue to Shine; Second Consequent 2023 Guidance Raise04 Nov 2023
- Otsuka Holdings (4578 JP): Strong 1H23 Result Prompts 2023 Guidance Raise; Pipeline Is Advancing13 Sep 2023
- Otsuka Holdings (4578 JP): Strong 2022 Result; 2023 Revenue to Hit Record-High Thanks to Key Drugs08 Apr 2023
- Otsuka Holdings (4578 JP): Revenue Guidance Raise and New Products Line-Up Enhance Conviction27 Jul 2022
- Otsuka Holdings (4578 JP) 1Q22: Global Products Continued Double-Digit Revenue Growth25 May 2022
- Otsuka Holdings (4578 JP): Well-Diversified Portfolio to Augment Revenue Growth08 Oct 2021
x